Skip to content

Sudden, severe headache? Call 911 (US)

HeadacheCare

Contemporary management of migrainous disorders in pregnancy

David Alexander M.D.Published January 10, 201122 min read
Contemporary management of migrainous disorders in pregnancy

Key points

  • Purpose of review: Migraine is a frequent event among women of reproductive age.
  • Summary: For those patients who develop debilitating migraine or whose migraines interfere with activities of daily living, there are several options for treatment and headache prevention that have a low likelihood of compromising fetal well being.
  • Epidemiology Approximately 10% of pregnant women will complain of headache before or during pregnancy.
  • Over 90% of patients with headache during pregnancy have a pre-existing headache and less than 10% of patients develop new-onset headache during pregnancy [4].

Purpose of review: Migraine is a frequent event among women of reproductive age. It is difficult to predict the course and severity of disease that migraineurs will endure during pregnancy. Treatment is often compromised during pregnancy because of concerns regarding pharmacotherapy and fetal well being.

Recent findings: The majority of women with migraine during pregnancy will not require ongoing pharmacotherapy or prophylaxis. Nonpharmacologic strategies should be the first-line treatment of migraines. For severe migraines, recent cohort studies documenting the use of triptans for treatment during pregnancy have shown no increase in adverse pregnancy and fetal outcomes above the average rate. High-dose valproate is the only antiepileptic drug available for migraine prophylaxis that has been shown to cause long-term cognitive effects in infants exposed during gestation. Congenital syndromes have been described for most of the older antiepileptic drugs but less so for many of the newer drugs. These newer medications appear to have improved safety profiles for use in pregnancy but there is still information lacking from larger patient cohorts and longitudinal studies of neurodevelopmental outcomes. There is also evidence to support use of beta-blockers and calcium-channel blockers for migraine prevention during pregnancy.

Summary: For those patients who develop debilitating migraine or whose migraines interfere with activities of daily living, there are several options for treatment and headache prevention that have a low likelihood of compromising fetal well being.

###

Introduction

Migraine headaches are periodic pain attacks on one or both sides of the head. Nausea, vomiting, photophobia, phonophobia, dizziness, blurry vision, cognitive disturbances, and other symptoms may accompany them. Some migraines do not include headache, and migraines may or may not be preceded by an aura [1].

Epidemiology

Approximately 10% of pregnant women will complain of headache before or during pregnancy. Most patients with chronic headaches have been diagnosed prior to pregnancy [3]. Occasionally patients develop new-onset headache with pregnancy that requires a diagnostic workup. Many patients will require some form of treatment during pregnancy. Therapy of migraine focuses on both prevention and treatment of symptoms. Pregnancy complicates management by limiting the use of medications that could potentially compromise fetal development, well being and long-term neurodevelopment. This article will focus on the quality of evidence supporting those therapies available for both headache treatment and prevention. We will also address the safety of pharmacotherapy during pregnancy.

Classification

Headaches during pregnancy may be primary or secondary. Primary headaches such as migraine and tension-type headaches often develop during the first half of pregnancy and improve during the later stages of pregnancy. Secondary headaches are most often due to vascular, tumor or infectious pathology and can appear at any time during pregnancy unless associated with hypertension, which most often develops in the third trimester.

Association with pregnancy

Over 90% of patients with headache during pregnancy have a pre-existing headache and less than 10% of patients develop new-onset headache during pregnancy [4]. Hormonal and vascular changes of pregnancy may influence the new onset of headache. Among those with pre-existing headache, over 80% are migraine and of those with new-onset headache, one-third is migraine and one-third is related to hypertension [4]. New-onset secondary headache in pregnancy is related to stroke and central venous thrombosis, arterio-venous malformations, brain tumors and benign intracranial hypertension [6]. Pregnant patients with new-onset migraine, pain that is worsening or that is different from usual migraines, with seizures, papilledema, or focal neurological signs or symptoms require a complete neurological evaluation since these characteristics are suggestive of secondary causes of headaches.

Approximately 50–80% of migraine and 30% of tension-type headache patients report improvement of symptoms during the third trimester [6–8]. Less than 30% of patients whose headache has not improved by the second trimester are likely to experience significant improvement throughout the rest of pregnancy [9]. Approximately half of patients experiencing relief during pregnancy will have a recurrence by 1 month postpartum [10].

Patient characteristics

Factors that are significantly associated with a complaint of migraine during pregnancy are a pregestational body mass index (BMI) of greater than 25 kg/m2, less than 5 h of sleep per night, unemployment, depression, sick leave during pregnancy, asthma, hypertension and discontinuation of serotonin-reuptake inhibitors.

Association with other medical conditions

There are several case-control and large cohort studies supporting an approximately two-fold increase in the incidence of preeclampsia among pregnant migraineurs. One case control study reported a higher frequency of chronic migraine among eclamptic compared to noneclamptic patients. This relationship was not seen for tension-type headaches [19]. Migraine with aura has been associated with a small increase in the absolute risk for stroke [20] and a significant increase in the relative risk for pregnancy related stroke [21].

Therapy

Preconceptional counseling regarding therapy for migraine headaches should be established to avoid unwanted fetal exposure to medications that have a potential teratogenic effect. If a patient is using pharmacotherapy and not using effective contraception, it is preferable to use a medication that is well tolerated during pregnancy.

Treatment categories

Although many pregnant women with mild headache will not require medication for pain management, approximately 70% of patients will require some form of intervention. The focus of therapy should be aggressive management of nausea, avoidance of nicotine, adequate hydration and sleep. When pharmacotherapy is required it should be tapered down to the lowest dose necessary for symptom control.

Behavior modification and physical therapy

Of the various alternative options for management of migraine, only relaxation and biofeedback have been shown to be effective during pregnancy [22]. Other alternative forms of therapy include lifestyle changes, physical therapy and exercise [40,41]. Lifestyle changes that could potentially impact outcome are adequate sleep, regular meals, and avoidance of nicotine.

Other alternative forms of management for migraine headache that are reported in the literature include closure of a patent foramen ovale [43]; however, this has not conclusively been shown to be effective [44] and its use for this purpose during pregnancy is not recommended.

Pharmacotherapy

This includes treatment for acute pain and preventive therapy to decrease the frequency of recurrences. The factors associated with the need for pharmacotherapy are migraine frequency and intensity, duration of symptoms, associated symptoms, degree of disability and interference with activities of daily living. The goals of migraine headache prophylaxis include reducing migraine frequency, severity, duration, and disability and improving the patient’s quality of life and ability to function. The choice of medication to be used depends on patient preference, efficacy, side effects and co-existing disease.

Patients with severe migraine headaches occurring more than two times a week should attempt alternative therapies or be treated with prophylactic medication [6]. The US FDA has a well known classification for drug categories in pregnancy. The categories often mislead healthcare providers and their patients to believe that risk increases from category A to X. Categories C, D, and X are based not just on risk, but risk weighed against benefit. That means that a drug in categories C or D may pose risks similar to a drug in category X. The categories do not always distinguish between risks based on human versus animal data findings or between differences in frequency, severity, and type of fetal developmental toxicities [46]. The FDA has proposed a new classification, which provides more clinically relevant information for each medication. It has four components: a fetal risk summary, a clinical considerations section, which includes information regarding inadvertent exposure, a prescribing statement and a data section. Until the recently proposed classification becomes available for clinical use, physicians will need to use the current classification. It is important to understand the implications of each category, which is not a progressive ranking but rather a descriptive category summarizing the quality, source and level of the evidence.

Migraine pain pharmacotherapy

Medications with proven efficacy in the management of acute headache include: triptans, acetaminophen, aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), and opioids.

Triptans have shown no increase in adverse pregnancy and fetal outcomes above the average rate. All triptans available in the US are considered to be pregnancy category C by the FDA. Sumatriptan is the most extensively studied of the triptans during pregnancy. Despite earlier concerns, the most recent information on triptans did not find an overall increased risk for congenital anomalies with their use. To place this in perspective, approximately 2–3% of newborns have a recognized structural defect at birth with an additional 3% having a defect diagnosed by 5 years of age [49]. In one recent large population-based study, the odds ratio (OR) for congenital anomalies with triptan use was 1.0 [95% confidence interval (CI) 0.7–1.2] [27]. However, there was a small increase in the risk of uterine atony and increased blood loss during the second or third trimesters [27]. At least one study reported an increase in the risk for preterm delivery [27,50,51]. Some studies have found an increase in the risk for congenital anomalies following first-trimester exposure to sumatriptan of 4.6% (95% CI 2.9–7.2%). These data were obtained from the Sumatriptan and Naratriptan in Pregnancy Registry and may be subject to reporting bias. The authors conclude that the results coupled with lack of epidemiological evidence to support a strong association are reassuring since the reported rates compare favorably with the 3–6% background rate at 5 years of age. Furthermore a thorough review of triptan use in pregnancy found that the available literature does not support different perinatal or pregnancy outcomes for patients exposed to triptans after conception [51].

NSAIDs are considered to be category C in the first and second trimester and category D in the third trimester of pregnancy. Two exceptions include aspirin, which is rated category D, and indomethacin, which is not recommended for use in pregnancy. Indomethacin is often used off-label for management of preterm labor prior to 32 weeks of gestation and at least one study has reported that aspirin is associated with an increase in the risk of miscarriage when used around the time of conception [hazard ratio of 1.8 (1.0–3.2)] [53]. This finding may have to do more with the reason the aspirin was prescribed. There are also concerns about premature closure of the ductus arteriosus when NSAIDs are used in the third trimester as well as bleeding abnormalities at the time of delivery [29]. These complications have not been observed when using aspirin at a dose of 60–100 mg/day [33]. A 2002 meta-analysis did not find evidence of an overall increase in risk of congenital defects associated with first-trimester use of aspirin [30].

Acetaminophen during pregnancy does not appear to increase the risk of adverse outcome and is rated class A by the FDA for use in pregnancy. There are conflicting results regarding an association between acetaminophen use during pregnancy and childhood wheezing or asthma. Acetaminophen is considered by many clinicians to be the analgesic and antipyretic medication of choice during pregnancy.

Opioids have limited efficacy in the management of migraines. All opioids are FDA category C for pregnancy. Although they are often used as a first-line option, they best serve as a second-tier medication when any of the previous options have not been successful in the treatment of migraines [6]. Their main drawback is the potential to aggravate headache symptoms secondary to withdrawal as well as increasing tolerance and dosing requirements with subsequent neonatal withdrawal. Short-acting medications such as hydrocodone are preferred.

Antiemetics are not very helpful as first-line therapy but rather as adjunctive therapy in conjunction with first-line pain medications to relieve the nausea and vomiting often associated with migraine headaches [54]. Most of the antiemetics are FDA pregnancy category C. Metoclopramide has peripheral activity on gastrointestinal motility and central dopaminergic inhibition. Ondansetron is a selective antagonist of the 5-HT3-serotonin receptor. Both of these medications are FDA pregnancy category B. Certain agents such as prochlorperazine are not rated for use in pregnancy. Treatment options automatically expand after delivery. The American Academy of Pediatrics has approved most analgesics and triptans for use while breastfeeding [55].

Migraine prophylactic pharmacotherapy

There are multiple drug classes used for prevention of migraine headaches. Classes of agents used to treat recurrent migraine prophylactically include alpha-adrenergic antagonists, calcium-channel blockers, beta 2-adrenergic agonists, serotonin antagonists, antidepressants, NSAIDs, and antiepileptic drugs.

Beta-blockers have the best record for safety and efficacy in the pregnant and nonpregnant population [56,57]. Propranolol and timolol are the only beta-blockers approved by the FDA for prevention of migraine, but metoprolol, nadolol, and atenolol have been used as well although there is less evidence supporting their use [58,59]. They are FDA rated as class C for use in pregnancy except atenolol, which is rated as class D. Beta-blockers can cause fatigue, exercise intolerance, depression, orthostatic hypotension, and decreased libido. All are relatively contraindicated in patients with asthma [60]. During pregnancy they have been used without evidence of teratogenic effects. Several studies have concluded that when these drugs are used throughout pregnancy they may produce adverse reactions such as intrauterine growth restriction (IUGR), cardiorespiratory depression, bradycardia, hypoglycemia, and hypothermia. In one systematic review on use of beta-blockers for hypertension in pregnancy, they appear to be no more effective and probably equally as well tolerated as methyldopa, hydralazine, nicardipine or isradipine [61,62]. The review also found that there was insufficient evidence to draw conclusions about the effects of ?-adrenoceptor antagonists on perinatal outcome [61].

The prevalence of major congenital malformations in offspring of women with epilepsy has ranged from 4 to 10%, corresponding to a two to four-fold increase from the expected prevalence in the general population. Data strongly suggest that this risk increase is caused mainly by antiepileptic drug exposure rather than epilepsy or seizures [63]. Valproate, gabapentin and topiramate are the antiepileptic drugs with proven efficacy for migraine prophylaxis in a nonpregnant population [39,64]. There is also evidence to support use of lamotrigine for migraine prophylaxis, particularly among patients with migraine associated with aura [39]. Significant reductions in migraine frequency have been reported with the use of valproate (50%), gabapentin (35%), and topiramate (30%) [65]. FDA approval for use in migraines has been granted for valproate and topiramate [66]. The FDA rates valproate as class D and topiramate as class C in pregnancy.

There is limited evidence regarding the efficacy and safety of gabapentin in the pregnant population [67,68]. Gabapentin is a class C drug in pregnancy by the FDA. It is an antiepileptic medication used for a variety of painful disorders, although its exact mechanism of action is unknown [69]. Gabapentin increases the percentage of headache-free days, decreases headache severity and disability, increases quality of life and reduces the amount of analgesic used [69].

Valproate has been shown to be effective for the prevention of migraine-type headaches based on several case-control and randomized trials [39,70]. The use of valproic acid during pregnancy is associated with a 1–2% incidence of neural tube defects. Patients who are unable to discontinue valproic acid during pregnancy must use folate supplements and be screened for neural tube defects.

Topiramate’s effectiveness has been confirmed in many studies with a decrease in the number of headache-affected days and a decrease in the requirement for pain medication. Topiramate produces abnormal outcomes in animal studies with an increase in craniofacial abnormalities [72]. Human case series and antiepileptic drug registries have identified abnormal pregnancy outcomes without a definitive increase in the incidence of congenital anomalies [73]. On the basis of this information it would seem advisable to avoid topiramate exposure during the first trimester.

Other antiepileptic drugs that have been used for migraine prevention include carbamazepine and oxcarbazepine, clonazepam, levetiracetam, zonisamide, tiagabine and vigabatrin. The evidence available either does not show a clinically significant effect or does not support their use for migraine prevention in nonpregnant individuals or pregnant women [39].

Tizanidine is an effective medication for headache prophylaxis, including migraine, migrainous headache, and tension-type headache. It has also been demonstrated to decrease the frequency, duration and intensity of headaches [74]. There is very limited information regarding its use in humans but animal studies suggest it can cause fetal skeletal anomalies. It is rated FDA category C for pregnancy.

Antidepressants are often considered for second-line prevention therapy [57]. In some studies, antidepressants have been associated with an increased rate of pregnancy loss in the first trimester but no increase in the rate of congenital anomalies [75]. Larger systemic reviews have not confirmed the increase in miscarriage rate for antidepressants in pregnancy [76].

Several antidepressants have been used for management of chronic headache and migraine. Evidence for their benefit is strongest for fluoxetine and amitriptyline [37,38]. The serotonin reuptake inhibitor fluoxetine has been demonstrated to be moderately effective in treating chronic headache. Fluoxetine is rated as a class C medication in pregnancy. It has been shown to cause a significant improvement in overall mood and a modest decrease in headache frequency [37]. The most recent Public Health Advisory published by the FDA states that the risk of primary pulmonary hypertension is increased among newborns exposed to selective serotonin reuptake inhibitors (SSRIs). About 0.1–0.2% of newborns in the US develop primary pulmonary hypertension shortly after birth. This complication was six times more common among infants of women who took an SSRI antidepressant after the 20th week of the pregnancy. The study reporting these results was too small to compare the risk in one drug compared to another [77]. Subsequent studies have not found this to be a consistent association and further studies are warranted [79]. The most concerning problem appears to be that infants of mothers taking SSRIs late in pregnancy may experience difficulties such as irritability, difficulty feeding and in very rare cases, difficulty breathing. In addition, paroxetine, an SSRI of unproven benefit in management of migraine in pregnancy, has been associated with an increase in the frequency of congenital heart defects (1.0% among mothers not taking any antidepressant versus 2.0% among mothers taking paroxetine). Among women treated for depression, the risk–benefit analysis would appear to favor ongoing use of these medications; however, no such analysis has been established for patients treated for migraine headaches [81].

Amitriptyline down-regulates serotonin receptors, increases synaptic norepinephrine, and enhances endogenous opioid receptor activity [38]. Its use is limited by the known side effects, including drowsiness, tachycardia and dry mouth [38]. The FDA rates this drug as category C for use in pregnancy.

Verapamil is a calcium-channel blocker with limited efficacy for migraine prevention [36]. It is considered a well tolerated option but not recommended as a first-line form of migraine prophylaxis during pregnancy [36]. The most important problem is a potential hemodynamic effect secondary to vasodilatation.

Pizotifen is a serotonin antagonist used in the treatment of vascular headache. Data regarding its effect on pregnancy are limited, but there are no reports of adverse outcomes during pregnancy. The FDA does not rate this medication for use during pregnancy. Methysergide is an ergot derivative and its use is contraindicated during pregnancy secondary to its vasoconstrictive effects.

It appears that initiating any therapy at low doses and slow gradual titration are important factors in preventing the side effects associated with their use during pregnancy [39].

Conclusion

Concerns about fetal harm or teratogenicity may interfere with prescription of the appropriate migraine headache treatments in pregnant patients. It is reassuring that over two-thirds of patients with migraine will improve during pregnancy, especially after the first trimester; therefore many physicians may defer treatment. In addition, it is prudent to limit prescription treatment for only moderate to severe headaches, but to aggressively treat nausea and vomiting to avoid dehydration. Many patients will be able to treat mild headaches with rest and adequate hydration, regular meals, biofeedback and relaxation in addition to first line pain medications.

Medications that are of concern secondary to their teratogenic potential may be the only option available for some patients. In this situation, patient preferences and thorough explanation of the risks and benefits, as well as adequate follow-up and surveillance can help detect and address abnormal outcomes.

In the pregnant population, beta-blockers, topiramate and gabapentin offer the most effective means of preventing recurrent migraine. Inadequately treated patients can lead to self-medication, poor nutrition and disability, which can compromise maternal infant bonding after delivery. Proactive care with preconceptional planning and planning for resurgence of migraines after delivery will improve outcomes for pregnant and recently delivered women.

It is unlikely that pregnant patients would be included in trials of new medications to treat migraine headaches. Collecting cases of medication exposure in patient registries will allow further compilation of patient outcome data.

###

Contag, Stephen Aa; Bushnell, Cherylb

aInstitute for Maternal Fetal Medicine, Sinai Hospital, Baltimore, Maryland, USA

bDepartment of Neurology and Women’s Health Center of Excellence, Wake Forest University Health Sciences, USA

Correspondence to Stephen A. Contag, Assistant Professor in Gynecology and Obstetrics, Johns Hopkins University, Baltimore, MD 21215, USA Tel: +1 410 601 9000; e-mail:

References

1 The International Classification of Headache Disorders: 2nd ed. Cephalalgia. 2004; 24 Suppl 1:9–160.

2•• Nezvalova-Henriksen K, Spigset O, Nordeng H. Maternal characteristics and migraine pharmacotherapy during pregnancy: cross-sectional analysis of data from a large cohort study. Cephalalgia 2009; 29:1267–1276.

3 Loder E. Migraine in pregnancy. Semin Neurol 2007; 27:425–433.

4 Melhado EM, Maciel JA Jr, Guerreiro CA. Headache during gestation: evaluation of 1101 women. Can J Neurol Sci 2007; 34:187–192.

5•• Lucas S. Medication use in the treatment of migraine during pregnancy and lactation. Curr Pain Headache Rep 2009; 13:392–398.

6 Marcus DA. Managing headache during pregnancy and lactation. Expert Rev Neurother 2008; 8:385–395.

7 Chen TC, Leviton A. Headache recurrence in pregnant women with migraine. Headache 1994; 34:107–110.

Get full article

Written by

David Alexander M.D.

Last updated

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. A sudden, severe headache, or one with weakness, confusion, fever or a stiff neck, needs emergency care: call 911 (US) or your local emergency number.

Migraine Comorbidity
Managing Your Headaches

Migraine Comorbidity

Migraine is associated with a number of neurologic and psychiatric disorders, including stroke, epilepsy, depression, and anxiety disorders. Feinstein (1970) coined the term “comorbidity,” which now refers to a greater than coincidental association of two conditions in the same individual

15 min read

The International Classification of Headache Disorders
Managing Your Headaches

The International Classification of Headache Disorders

1. [G43] Migraine 2. [G44.2] Tension-type headache (TTH) 3. [G44.0] Cluster headache and other trigeminal autonomic cephalalgias 4. [G44.80] Other primary headaches 5. [G44.88] Headache attributed to head and/or neck trauma 6. [G44.81] Headache attributed to cranial or cervical vascular

17 min read

When a headache is an emergency

Know the warning signs.

Most headaches are not dangerous, but some need care right away. If you or someone near you has any of these, call 911 (US) or your local emergency number.